Related Experiment Videos
Cryosurgery for prostate cancer: new technology and indications
R M Benoit1, J K Cohen, R J Miller
1Department of Urology, Allegheny General Hospital, 1209 Allegheny Tower, 625 Stanwix Street, Pittsburgh, PA 15222, USA. Rbenoit@triangleurology.com
Current Urology Reports
|June 27, 2002
Summary
Cryosurgical ablation of the prostate (CSAP) is a viable primary treatment for high-risk localized prostate cancer. It also serves as a preferred option for recurrent prostate cancer after radiation therapy, offering good cancer control with manageable side effects.
Area of Science:
- Urology
- Oncology
- Surgical Innovation
Background:
- Prostate cancer treatment involves choosing from various options for similar-stage disease.
- Radical prostatectomy, external beam radiation, prostate brachytherapy (PB), and cryosurgical ablation of the prostate (CSAP) are established treatments.
Purpose of the Study:
- To review the current role of cryosurgical ablation of the prostate (CSAP) in treating clinically localized prostate cancer.
- To evaluate CSAP's efficacy and safety in specific patient populations.
Main Methods:
- Review of current literature and clinical data on CSAP for prostate cancer.
- Analysis of treatment outcomes, including cancer control rates and side-effect profiles.
Main Results:
- CSAP is indicated for primary treatment in high-risk localized prostate cancer (PSA >10, Gleason score ≥7, or cT2B).
- CSAP, sometimes combined with external beam radiotherapy, shows improved cancer control for high-risk prostate cancer compared to other therapies.
- CSAP demonstrates an acceptable side-effect profile.
Conclusions:
- CSAP is a suitable primary treatment for high-risk localized prostate cancer.
- CSAP is the recommended treatment for localized recurrent prostate cancer following prior radiotherapy (external beam or PB).